The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
ATP Binding Cassette Transporter, Subfamily B, Member 1
/ antagonists & inhibitors
ATP Binding Cassette Transporter, Subfamily G, Member 2
/ drug effects
Administration, Oral
Adult
Aged
Biological Availability
Cladribine
/ administration & dosage
Cytochrome P-450 Enzyme System
/ metabolism
Equilibrative Nucleoside Transporter 1
/ drug effects
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Lymphocytes
/ drug effects
Male
Membrane Transport Proteins
/ drug effects
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ drug therapy
Neoplasm Proteins
/ drug effects
Pharmacology, Clinical
Protein Binding
/ drug effects
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
11
7
2018
medline:
23
5
2020
entrez:
11
7
2018
Statut:
ppublish
Résumé
Cladribine Tablets (MAVENCLAD
Identifiants
pubmed: 29987837
doi: 10.1007/s40262-018-0695-9
pii: 10.1007/s40262-018-0695-9
pmc: PMC6373393
doi:
Substances chimiques
ABCG2 protein, human
0
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
ATP Binding Cassette Transporter, Subfamily G, Member 2
0
Equilibrative Nucleoside Transporter 1
0
Immunosuppressive Agents
0
Membrane Transport Proteins
0
Neoplasm Proteins
0
cif nucleoside transporter
0
Cladribine
47M74X9YT5
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-297Commentaires et corrections
Type : ErratumIn
Références
Curr Opin Neurol. 2018 Jun;31(3):233-243
pubmed: 29634596
Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48
pubmed: 27640924
J Clin Pharmacol. 2008 Jan;48(1):13-8
pubmed: 18094216
Leukemia. 2004 Mar;18(3):385-93
pubmed: 14737075
Cancer Res. 2007 Jul 15;67(14):6965-72
pubmed: 17638908
Br J Haematol. 2009 Jan;144(1):136-7
pubmed: 19016729
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
BMC Pharmacol. 2005 Mar 09;5:4
pubmed: 15757511
Clin Pharmacokinet. 2017 Oct;56(10):1245-1253
pubmed: 28255849
Clin Cancer Res. 1998 Mar;4(3):653-8
pubmed: 9533533
Xenobiotica. 2013 Dec;43(12):1084-94
pubmed: 23627543
Mol Cancer Ther. 2008 Sep;7(9):3092-102
pubmed: 18765824
AAPS J. 2017 Jan;19(1):172-179
pubmed: 27634384
J Clin Oncol. 1996 Mar;14(3):978-83
pubmed: 8622049
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1324-40
pubmed: 22132993
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Lancet. 1992 Oct 17;340(8825):952-6
pubmed: 1357355
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Expert Opin Pharmacother. 2013 Jan;14(1):123-36
pubmed: 23256518
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Eur J Pharm Sci. 2004 Jan;21(1):25-51
pubmed: 14706810
Neurology. 2016 Apr 5;86(14):1279-1286
pubmed: 26962066
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40
pubmed: 23383731
Leukemia. 2000 Jan;14(1):52-60
pubmed: 10637477
Cancer Res. 1994 Mar 1;54(5):1235-9
pubmed: 7906999
Am J Physiol Renal Physiol. 2009 Jun;296(6):F1439-51
pubmed: 19297449
J Clin Pharmacol. 2018 Oct;58(10):1284-1294
pubmed: 29746722
Nat Rev Neurol. 2017 Oct;13(10):573-574
pubmed: 28884753
Clin Pharmacokinet. 1997 Feb;32(2):120-31
pubmed: 9068927
Clin Pharmacokinet. 2019 Mar;58(3):325-333
pubmed: 29992396